# Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

> **NCT00657150** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2055 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Dabigatran etexilate

## Key facts

- **NCT ID:** NCT00657150
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 2055 (ACTUAL)
- **Last updated:** 2014-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657150, "Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00657150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*